Pharming receives EMA approval of new facility for expansion of RUCONEST® production
Pharming Group today announced it has received European Medicines Agency (EMA) approval of a Type II Variation for a new production facility for its lead product, RUCONEST®.
- New production facility will significantly increase production capacity of RUCONEST®
- Product manufactured at the new facility during the approval process is now available for distribution within the EU
As we continue to see increasing demand for RUCONEST® in the treatment of HAE, we are pleased to announce the approval of our new facility, which will enable us to significantly increase production capacity for supply to patients in the EU- Sijmen de Vries - CEO